

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 36193	SERIAL NO. 10/536,584
		APPLICANT: MESSADEK, Jallal	
		FILING DATE: April 7, 2006	GROUP: 1615 Conf. 9204

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5 8 8 0 0 9 8	9/3/99	Haussinger			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	PUB DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	0 7 8 1 5 5 4	02.07.96	EPO			X
	9 8 1 9 6 9 0	14.05.98	WO			X
	9 5 1 5 7 5 0	15.06.95	WO			X
	9 7 3 8 6 8 5	23.10.97	WO			X
	0 3 4 7 8 6 4	27.12.89	EPO			X
	0 0 2 5 7 6 4	11.05.00	WO			X
	9 7 9 6 7 6 9	27.02.97	WO			X
	2 1 9 1 2 2 B	28.09.92	HU			X
1	6 3 2 8 3 8 5	23.05.00	JP			X (abstract only)
	0 0 5 1 5 9 6	08.09.00	WO			X
	0 3 4 9 9 0 2	10.01.90	EPO			X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Savi et al., Abstract from Entrez-PubMed web page entitled "SR 121787, a new orally active fibrinogen receptor antagonist," Thromb Haemost, 1998 Sep;80(3):469-76, 1 page
	Banno et al., Abstract from Entrez-PubMed web page entitled "Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein IIb/IIIa receptor antagonist," Eur J Pharmacol., 1999 Feb 19;367(2-3):275-82, 1 page
	Ramjit et al., Abstract from Entrez-PubMed web page entitled "Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis," J Pharmacol Exp Ther., 1993 Sep;266(3):1501-11, 2 pages
	Hoffmann et al., Abstract from Entrez-PubMed web page entitled "Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein IIb/IIIa antagonist," J Pharmacol Exp Ther., 1998 Aug;286(2):670-5, 1 page
	Packham, Abstract from Entrez-PubMed web page entitled "Role of platelets in thrombosis and hemostasis," Can J Physiol Pharmacol., 1994 Mar;72(3):278-84, 1 page
	Lynch et al., Abstract from Entrez-PubMed web page entitled "Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383," J Pharmacol Exp Ther., 1995 Jan;272(1):20-32, 2 pages
	Katada et al., Abstract from Entrez-PubMed web page entitled "The in vitro and in vivo pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403," Thromb Res., 1997 Oct 1;88(1):27-70, 1 page

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 36193	SERIAL NO. 10/536,584
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: MESSADEK, Jallal	
(Use several sheets if necessary)		FILING DATE: April 7, 2006	GROUP: 1615 Conf. 9204

U.S. PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Ogawa et al., Abstract from Entrez-PubMed web page entitled "Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs," Thromb Res., 2000 Mar 1;97(5):307-15., 1 page
	Zapadniuk, Abstract from Entrez-PubMed web page entitled "Cholagogic effect of trimethylglycine in normal animals of different ages and in experimental atherosclerosis," Biull Eksp Biol Med., 1987 Jul;104(7):30-2., 2 pages
	Panteleimonova, Abstract from Entrez-PubMed web page entitled "Effect of trimethylglycine on lipid metabolism in experimental atherosclerosis in rabbits," Farmakol Toksikol., 1983 Jul-Aug;46(4):83-5., 1 page
	Fazio et al., "Treatment of Human Atherosclerosis with Betaine," Minerva Med., 1981 Apr 25, pp. 1511-1516, XP-000853747
	P. H. List et al., "Hagers Handbuch Der Pharmazeutischen Praxis," 1972, Pringer Verlag, Berlin Heidelberg, New York, page 431, XP-002123167
	Wilcken et al., "The natural history of vascular disease in homocystinuria and the effects of treatment," J. Inher. Metab. Dis. 20(1997) 295-230.
	Betaine for Homocystinuria, The Medical Letter, Vol 39, Issue 593, January 31, 1997, page 12, XP-000853853
	Reynolds, Betaine Hydrochloride, Matindale, The Extra Pharmacopoeia, 1996, Royal Pharmaceutical Society, London, page 1679, XP-002123168
	1225 Betaine, The Merck Index, 1996 Merck and Co., Whitehouse Stations, NJ, p. 198, XP-002123169
	Mar et al., Abstract from Entrez-PubMed web page entitled "Betaine in wine: answer to the French paradox?" Med Hypotheses, 1999 Nov;53(5):383-5., 2 pages
	Salamone et al., "Changes in blood coagulation in experimental subacute poisoning with p-dichlorobenzene. The influence of some lipotropic factors," Journal, Answer 13 of 13, Copyright 2003, ACS, 1 page
	Vinson et al., "New Drug Approvals of 1996 Part 3," Drug Topics, March 17, 1997, University of Mississippi School of Pharmacy, pp. 72-81.
	Reynolds, Betaine, Pharmacopoeia, Applied Pharma Research, P&B Publications Ltd., Richmond, Surrey, UK, XP-002202249, pp. 1-2. (no date)
	Matthews et al., "An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria," 2002 Blackwell Scient Ltd Br J Clin Pharmacol, 54, 140-146.
	Schwahn et al., "Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria," 2003 Blackwell Scient Ltd Br J Clin Pharmacol, 55, 6-13.
	Reynolds, monography from http://www.mdit.com, Clinical Pharmacology, pp. 1-2 (no date)

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance with MPEP 609. All REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. J.V./

FORM PTO-1449 (Rev 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 36193	SERIAL NO. 10/536,584
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT: Jallal Messadek	
		FILING DATE: April 7, 2006	GROUP: 1615 CONF. NO: 9204

U.S. PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	INVENTOR NAME	CLASS	SUB- CLASS	ISSUE DATE (PATENT); PUBLICATION DATE (PUBLISHED APPLICATION); OR FILING DATE (NON-PUBLISHED APPLICATION)
	6 2 8 7 7 6 5	Cubiciotti			September 11, 2001
	US 2002/0034757	Cubiciotti			March 21, 2002
	5 9 2 8 1 9 5	Malamud et al.			July 27, 1999
	6 3 9 9 7 8 5	Murphy et al			June 4, 2002
	6 8 5 5 7 3 4	Messadek			February 15, 2005

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
					YES NO

OTHER DOCUMENTS (Including Publisher, Author, Title, Relevant Pages, and Date and Place of Publication)

	Bandfield et al., "Naproxen, Naproxen Sodium, and Naproxen Betainate Sodium Monohydrate Salts," Pharmaceutics 1, April 14, 2001, pp. 1-5
	van Hecken et al., Abstract from Entrez-PubMed web page entitled "Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers," Drug Metabol Drug Interact, 1998;14(3):193-205, 1 page
	EC-Naprosyn, Naprosyn, Anaprox, Naprosyn, Rx Only, Roche Pharmaceuticals, Copyright 1999-2004 by Roche Laboratories Inc., pp. 1-20
	Environmental and Health Assessment of Substances in Household Detergents and Cosmetic Detergent Products. Environment Project, 615, 2001, 6 1 Betaines, http www2.mst.dk/common/Udgivramme/Frame.asp?pg=http://www2.mst.dk/udgiv/Publications/2001/87-7944-596- 9/html/telepubt_eng.htm, 1 page
	NIAD Home/NIAD HIV/OI Chemical Compound Search/Anti HIV/OI Chemical Compound Results, http chemdb.niad.nih.gov/struct_search/all/url_search.asp?aid_no=008188, 1 page (no date)
	Wyryck P B et al., The Microbicidal Agent C31G Inhibits Chlamydia Trachomatis Infectivity in vitro., <u>Antimicrob Agents Chemother</u> , 1997 June, 41(6): 1335-44, PMID: 9174195, 1 page
	Thompson, K.A. et al., Assessment of the Anti-Microbial Agent C31G as a Spermicide: Comparison with Nonoxonyl-9, <u>Contraception</u> , 1996 May, 53(5): 313-8, PMID: 8724622, 1 page

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.V./

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 36193	SERIAL NO. 10/536,584
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT: Jallal Messadek	
		FILING DATE: April 7, 2006	GROUP: 1615 CONF. NO: 9204

U.S. PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	INVENTOR NAME	CLASS	SUB- CLASS	ISSUE DATE (PATENT); PUBLICATION DATE (PUBLISHED APPLICATION); OR FILING DATE (NON-PUBLISHED APPLICATION)
	US 2004/0033223	Messadek			February 19, 2004
	4 0 6 6 7 5 6	Orr et al.			January 3, 1978
	4 7 0 3 0 4 5	Guinot			October 27, 1987
	5 8 7 6 7 8 0	Vertanen			March 2, 1999
	5 9 6 1 9 9 9	Birczok et al.			October 5, 1999

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
					YES NO

OTHER DOCUMENTS (Including Publisher, Author, Title,
Relevant Pages, and Date and Place of Publication)

	Rogers J S., Abstract from Entrez-PubMed web page entitled "Hypercoagulable states," W V Med J., 1993 Feb 89(2):61-3, 1 page
	Nielsen H.K., Abstract from Entrez-PubMed web page entitled "Pathophysiology of venous thromboembolism," Semin Thromb Hemost. 1991;17 Suppl 3:250-3, 1 page
	Silver et al., Abstract from Entrez-PubMed web page entitled "The caput medusae of hypercoagulability," J. Vasc. Surg., 2000 Feb;31(2):396-405, 1 page
	Swan M.A., "Improved Preservation of the Ram Spermatozoan Plasma Membrane using Betaine in the Primary Fixative," J. Microsc., 1997 Sept., 187(pt 3): 167-9, PMID: 9351233, 1 page
	Thomas K.C. et al., "Effects of Particulate Materials and Osmoprotectants on Very-High-Gravity Ethanollic Fermentation by Saccharomyces Cerevisiae," Appl Environ Microbiol. 1994 May, 60(5): 1519-24, PMID: 801734, 1 page
	Chambers, S. et al., The Osmoprotective Properties of Urine for Bacteria: The Protective Effect of Betaine and Human Urine Against Low pH and High Concentrations of Electrolytes, Sugars, and Urea, J. Infect Dis., 1985 Dec, 152(6): 1308-16, PMID: 3905986, 1 page
	Smith, L.T., Role of Osmolytes in Adaptation of Osmotically Stressed and Chill-Stressed Listeria Monocytogenes Grown in Liquid Media and on Processed Meat Surfaces, Appl Environ Microbiol, 1996 Sept., 62(9): 3088-93, PMID: 8795194, 1 page
	Peddie B.A. et al., Is the Ability of Urinary Tract Pathogens to Accumulate Glycine Betaine a Factor in the Virulence of Pathogenic Strains?, J. Lab. Clin. Med., 1996 Oct., 128(4): 417-22, PMID: 8833891, 1 page
	Koskinen, E. et al., A Preliminary Study on the Use of Betaine as a Cryoprotective Agent in Deep Freezing of Stallion Semen, Zentralbl Veterinärmed A., 1989 Feb., 36(2): 110-4, PMID: 2501949, 1 page
	Swan M.A., Improved Preservation of Ultrastructural Morphology in Human Spermatozoa Using Betaine in the Primary Fixative, Int. J. Androl., 1997 Feb 20(1): 45-54, PMID: 9202990, 1 page

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.V./

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 36193	SERIAL NO. 10/536,584
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT: Jallal Messadek	
		FILING DATE: April 7, 2006	GROUP: 1615 CONF. NO: 9204

U.S. PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER							INVENTOR NAME	CLASS	SUB-CLASS	ISSUE DATE (PATENT); PUBLICATION DATE (PUBLISHED APPLICATION); OR FILING DATE (NON-PUBLISHED APPLICATION)
	6	2	3	5	3	1	1	Ullah et al.			May 22, 2001
	6	3	5	5	1	6	6	Amarasinghe et al.			March 12, 2002
	6	4	7	6	0	0	6	Flashner-Barak et al.			November 5, 2002

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER							PUBLICATION DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
												YES	NO
	DE 19910682							September 21, 2000	Germany			X (abs- tract only)	
	JP 2000-143486							May 23, 2000	Japan			X (abs- tract only)	
	BE 1012546 (09900164)							December 5, 2000	Belgium			X (abs- tract only)	
	BE 1012712 (09900403)							February 6, 2001	Belgium			X (abs- tract only)	
	BE 2003/0248							April 17, 2003	Belgium			X (abs- tract only)	
	FR 77 29075 (2 403 799)							September 27, 1977	France			X (Google trans- lation only)	

**OTHER DOCUMENTS (Including Publisher, Author, Title,
Relevant Pages, and Date and Place of Publication)**

/Jale Vu/ 02/24/2010

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.V./